 |
|
|
| |
Clinically meaningful rates of functional cure in virologically suppressed patients with chronic hepatitis B infection treated with bepirovirsen: B-Well Phase 3 Trials
|
| |
| |
EASL 2026 May 26-30 Barcelona
Professor Seng-Gee Lim, National University Health System, Singapore, on behalf of the B-Well Study Group
Jinlin Hou*, Seng-Gee Lim*, Maria Buti, Man-Fung Yuen, Edward Gane, Pietro Lampertico, Norah Terrault, Huy Nguyen, Hyung Joon Yim, Qing Xie, Jianmei Lin, Yunqing Qiu, Wen-Juei Jeng, Jeong Heo, Cheng-Yuan Peng, Chien-Hung Chen, Wan-Long Chuang, Yao Xie, Maria Hlebowicz, Nevin Idriz, Rajiv Mehta, Kosh Agarwal, Monica M. Gomes da Silva, Alex Franca, Roxana Cernat, Apinya Leerapun, Carla S. Coffin, Adrian Gadano, Pietro Andreone, Shigetoshi Fujiyama, Vasileios Sevastianos, Yuichiro Suzuki, Vlad Ratziu, Ghassan Riachi, Hartmut Stocker, Tien Huey Lim, Tarik Asselah, Yasuhito Tanaka, Jacinta Holmes, Xieer Liang, Jennifer Cremer, Tamara Lukic, Helene Plein, Geoff Quinn, Yu Tao, Melanie Paff, Dickens Theodore, Robert Elston, for the B-Well Study Group
|
| |
|
|
|
|
|
